R&D trend #5: The top execs in biotech are riding a boom — but there’s one big step left
Over the past few months I’ve been enjoying watching some serial entrepreneurs doubling down on their expertise. Greg Verdine called recently about his second ongoing startup and launch round and Michael Gilman talked up his plans to hatch another company as the first A round on his third biotech startup was rolling out.
These days, drug development is more project oriented than ever. Small teams under an experienced guiding hand can accomplish a lot. They are tailor-made for nailing down proof-of-concept data.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.